Mecasermin: Difference between revisions
Content deleted Content added
added FDA approval for use in a trial for ALS |
Noah Salzman (talk | contribs) add ref |
||
| Line 28: | Line 28: | ||
'''Mecasermin''', also known as mecasermin rinfabate (brand names '''Increlex''' and '''Iplex''') is a [[growth hormone]] which is used for the long-term treatment of growth failure in children with severe primary IGF-1 deficiency. |
'''Mecasermin''', also known as mecasermin rinfabate (brand names '''Increlex''' and '''Iplex''') is a [[growth hormone]] which is used for the long-term treatment of growth failure in children with severe primary IGF-1 deficiency. |
||
On March 11, 2009 the [[U.S. Food and Drug Administration|FDA]] announced that mecaserim would be made available to Americans with [[amyotrophic lateral sclerosis]], more commonly known as Lou Gehrig's disease, as a part of a [[clinical trial]]. The drug is currently available in [[Italy]] for this condition.<ref>{{citeweb|url=http://online.wsj.com/article/SB123672769945188703.html|title=FDA Allows Use of Drug for ALS|accessdate=2009-03-11|author=Jennifer Corbett Dooren|date= |
On March 11, 2009 the [[U.S. Food and Drug Administration|FDA]] announced that mecaserim would be made available to Americans with [[amyotrophic lateral sclerosis]], more commonly known as Lou Gehrig's disease, as a part of a [[clinical trial]]. The drug is currently available in [[Italy]] for this condition.<ref>{{citeweb|url=http://online.wsj.com/article/SB123672769945188703.html|title=FDA Allows Use of Drug for ALS|accessdate=2009-03-11|author=Jennifer Corbett Dooren|date=2009-03-10|work=Wall Street Journal|publisher=}}</ref><ref>{{citeweb|url=http://www.nytimes.com/2009/05/17/health/policy/17untested.html|title=Fighting for a Last Chance at Life|accessdate=2009-05-17|author=Amy Harmon|date=2009-05-17|work=The New York Times}}</ref> |
||
== References == |
== References == |
||
Revision as of 04:37, 17 May 2009
 |
| Clinical data | |
|---|---|
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status |
|
Mecasermin, also known as mecasermin rinfabate (brand names Increlex and Iplex) is a growth hormone which is used for the long-term treatment of growth failure in children with severe primary IGF-1 deficiency.
On March 11, 2009 the FDA announced that mecaserim would be made available to Americans with amyotrophic lateral sclerosis, more commonly known as Lou Gehrig's disease, as a part of a clinical trial. The drug is currently available in Italy for this condition.[1][2]
References
- ^ Jennifer Corbett Dooren (2009-03-10). "FDA Allows Use of Drug for ALS". Wall Street Journal. Retrieved 2009-03-11.
- ^ Amy Harmon (2009-05-17). "Fighting for a Last Chance at Life". The New York Times. Retrieved 2009-05-17.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
